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Clinicopathologic Changes in Children with 
Immuno globulin A Nephritis and Henoch-
Schönlein Purpura Nephritis after Cyclosporine 
A and Angiotensin-con verting Enzyme Inhibitor 
Treatment
Purpose: To investigate the clinicopathologic effects of cyclosporine A (CsA) in 
children with diseases characterized by mesangial immunoglobulin A deposits 
such as im mu noglobulin A nephropathy (IgAN) and Henoch-Schönlein purpura 
nephritis (HSPN).
Methods: We retrospectively reviewed the clinicopathologic outcomes of 54 
children (IgAN, 36; HSPN, 18) treated with CsA. The starting dose of CsA was 5 
mg/kg per day, and it was administered in 2 divided doses. The degree of prote-
inuria and pathologic changes in renal biopsies were evaluated before and after 
CsA treatment.
Results: The mean protein to creatinine ratio decreased from 3.7±1.5 to 0.6±0.4 
(P<0.001), and 32 (59.2%) children achieved complete remission of proteinuria 
after 1-year CsA treatment. Among the 54 children, 24 maintained normal renal 
function and 25 exhibited microscopic hematuria or proteinuria at the end of 
CsA treatment. In the HSPN group, 3 children whose initial biopsies indicated class 
IIIb disease showed class II disease on follow-up, and the follow-up biopsies of 2 
chil dren who had class II disease indicated the same class II disease. In the IgAN 
group, cortical tubular atrophy occurred in 1 child, and no child with IgAN had 
cortical interstitial fibrosis or tubular atrophy after 1-year CsA treatment. No 
significant complications were found in the children treated with CsA.
Conclusion: Our findings indicate that CsA treatment is effective and beneficial 
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Introduction
Both immunoglobulin A nephropathy (IgAN) and 
Henoch-Schönlein purpura nephritis (HSPN), affecting 
glomerular function and structures, are pathologically 
characterized by mesangial deposits of IgA. Among se-
veral immunoglobulins, IgA is unique for its capability to 
form multimers, and circulating IgA-containing immune 
complexes have been demonstrated in both illnesses 
related to the deposits of IgA and IgA-containing immune 
complexes in the glomerular mesangium [1].
Characterized by prominent diffuse mesangial IgA 
deposits on immunofluorescence microscopy, primary 
IgA nephropathy was initially thought to be a rare but 
benign cause of recurrent hematuria [2]. However, the 
clinical course of IgAN is variable, with some patients 
having stable renal function over decades and others 
developing hypertension, nephrotic syndrome, and 
chronic renal failure [2]. A number of clinical and histo-
logical prognostic markers, including impairment of renal 
function, severe proteinuria, and high blood pressure, 
predict a poor outcome [3].
HSPN, a leucocytoclastic vasculitis, is caused by mainly 
IgA1-mediated inflammation of small vessels [4-7]. 
Although isolated microscopic hematuria is the more fre-
quent clinical presentation of HSPN, nephritic syndrome 
and acute nephritic syndrome, often with hypertension, 
are observed in about half of the cases [4-7]. Renal in-
volvement occurs in 30-90% of HSP patients [8]. The 
severity of renal symptoms at onset is known to be the 
most prognostic factor for HSP in children; patients pre senting 
with nephrotic-range proteinuria or severe nephritis have 
the highest risk of unfavorable prognosis [9].
Patients with IgAN or HSPN should be treated properly 
at an early stage to prevent rapid progress to renal in-
sufficiency. Although the management of the two dis-
eases characterized by IgA deposits still remains elusive, 
recent studies have suggested that cyclosporin A (CsA) 
might have a beneficial effect in children with severe 
IgA deposits [10-15]. However, the number of patients 
included in those studies was limited, and the glomerular 
changes in IgAN were categorized according to the Haas 
classification [13]. Therefore, we aimed to investigate 
clinicopathologic effects of CsA on children with glo-
merular IgA deposits by histologically classifying HSPN 
according to the International Study of Kidney Disease 
in Childhood and IgAN according to the Oxford classi-
fication instead of the Haas classification. 
 
Materials and Methods
1. Patients
We retrospectively reviewed a total of 54 patients 
(IgAN:HSPN=36:18; M:F=32:22) treated with CsA from 
2005 to 2012 in our hospital. Of 42 HSP patients that we 
reviewed, 25 were younger than 10 years of age, and 
23 HSP patients were boys. Among the 42 HSP patients, 
18 children developed HSPN and were treated with CsA 
due to nephrotic-range proteinuria. Nephrotic-range 
proteinuria was defined as IgAN or HSPN patients had 
proteinuria greater than 40 mg/m2/hr. Six IgAN and 
six HSPN patients underwent repeated renal biopsies 
before and after CsA treatment, respectively. Both of 
the patients with IgAN and HSPN showed microscopic 
hematuria at diagnosis. Thirty children experienced 
nephrotic syndrome after diagnosis of IgAN and HSPN, 
and the remaining patients showed nephrotic-range 
proteinuria except two IgAN patients. 
2. Treatment protocol
CsA was administered to the patients with diseases 
in reducing massive proteinuria and preventing progression to end-stage renal failure in children with glomerular diseases 
characterized by IgA deposits, such as IgAN and HSPN, within 1 year of treatment.
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characterized with IgA deposits such as IgAN or HSPN 
when the patients showed nephrotic syndrome or 
nephrotic-range proteinuria. Angiotensin-converting 
enzyme inhibitor (ACEi) was concurrently used in all 
patients during the period of treatment with CsA, where 
as corticosteroids were not used for the treatment of the 
patients. The starting dose of CsA was 5 mg/kg/day in two 
divided doses, and the desired drug level was maintained 
between 100 and 200 ng/mL. CsA levels were measured 
every 2 weeks at the beginning of treatment and every 
two months during the maintenance period.
3. Renal biopsy
Renal specimens of HSP patients were graded by 
the histological classification of ISKDC: grade I, minor 
glomerular abnormalities; grade II, pure mesangial 
proli feration (a: focal; b: diffuse); grade III, minor glom-
erular abnormalities or mesangial proliferation with 
crescents/segmental lesion in <50% crescents (a: focal; 
b: diffuse mesangial proliferation); grade IV, mesangial 
proliferation with crescents/segmental lesions in 50-75 
% glomeruli (a: focal; b: diffuse mesangial proliferation); 
grade V, mesangial proliferation with crescents/segmental 
lesions in >75% glo meruli (a: focal; b: diffuse mesangial 
proliferation); grade VI, membranoproliferative-like 
lesion (10). For an active lesion index, the scoring was 
assessed as follows: 1) me sangial proliferation: normal 
(0), slight (1), moderate (2), and severe (3); 2) necrosis or 
cellular crescents: 0% (0), 1-20% (1), 20-50% (2), >50% of 
glomeruli. The chronicity index was evaluated as follows: 1) 
fibrous crescents or global sclerosis: 0% (0), 1-20% (1), 20-
50% (2), >50% of glomeruli (3); tubular atrophy associated 
with interstitial fibrosis: 0 (0%), 1-20% (1), 20-50% (2), >50% 
of cortical area (3).   
Clinicopathologic classification with pathologic features 
predictive of disease progression was graded using the 
Oxford Classification system (2009) of IgAN. The key 
pathologic features to be reported on renal biopsy were 
scored as follows: 1) mesangial hypercellularity: mean 
<4 mesangial cells/mesangial area (M0) and mean 4 or 
more mesangial cells/mesangial area (M1); 2) segmental 
glo merulosclerosis or adhesions present (S1) or absent 
(S0); 3) endocapillary proliferation present (E1) or 
absent (E0); 4) cortical interstitial fibrosis and tubular 
atrophy 0-25% (T0), 26-50% (T1), and >50% (T2); 5) 
total number of glomeruli with changes: endocapillary 
hypercellulariity, extracapillary proliferation, global 
glomerulosclerosis, and segmental glomerulosclerosis 
[11, 12]. Each pathologist from two different universities 
completed a scoring sheet for every biopsy and these 
data were used to obtain a consensus for each parameter. 
4. Clinical status evaluation
The clinical status of each patient at diagnosis and at 
the most recent observation was classified as follows: 1) 
state A, normal physical examination, urine, and renal 
function; 2) state B1, microscopic hematuria without 
proteinuria; 3) state B2, proteinuria <40 mg/m2/hr with 
or without hematuria; 4) state C, active renal disease 
cha racterized by hypertension or proteinuria of 40 mg/
m2/hr or greater, with glomerular filtration rate (GFR) of 
60 mL/min/1.73m2 or greater.
5. Statistical analysis
Statistical analyses were performed with SPSS for 
Windows version 18.0 (SPSS, Chicago, Illinois, USA). 
Descriptive statistics were expressed as mean±standard 
deviation or as a median with ranges. Differences bet-
ween parameters before and after CsA treatment were 
compared with the Wilcoxon signed rank test and non-
parametric statistical methods. All differences were 
considered sta tistically significant at P<0.05.
Results
The mean age of the patients was 10±4.2 year (range 
2.0-16) at the time of HSPN or IgAN diagnosis (Table 
1). No patient showed renal failure, hypertension, or 
acute nephritic features at onset. Among 54 patients with 
micro scopic hematuria, 36 (66.7%) had gross hematuria 
at the time of the initial examination (Table 1). Mean 
duration of CsA treatment was 11.7±5.6 months (range 
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10.4-12.7). Angiotensin-converting enzyme inhibitor was 
maintained for the duration of CsA treatment (mean 14.5
±24.2 months). Mean period of 3.0±2.6 months (range 
1.3-12.6) was needed to normalize massive proteinuria 
after treatment of CsA. The median duration of follow-
up was 3.7±3.1 year (range 1.7-15.2) from the onset of 
disease.
The mean serum levels of total protein and albumin 
increased from 6.5±0.8 g/dL to 7.1±0.4 g/dL (P<0.001) 
and from 2.8±0.6 g/dL to 4.3±0.2 g/dL (both P<0.001), 
re spectively, after CsA treatment (Table 2). Mean cholesterol 
level decreased significantly from 205.9±77.9 mg/dL to 
166.0±44.0 mg/dL (P<0.001), whereas serum creatinine 
level increased from 0.6±0.2 mg/dL to 0.7±0.2 mg/dL 
(P=0.005). Of note, the uric acid level significantly in-
creased from 4.8±1.3 to 5.3±1.6 (P=0.004) (Table 2). 
The pretreatment and follow-up renal biopsy results 
for 6 IgAN and 6 HSPN children are shown in Table 3. 
After 1-year treatment of CsA, one child with HSPN had 
ISKDC IIIb at the second biopsy from initial IIIa. Three 
children whose initial biopsies were class IIIb had class 
II disease on follow-up, and follow-up biopsies of two 
children with class II had the same class II in HSPN 
(Table 3). According to Oxford classification of IgAN, 
one children had M1S1, one had M1E1, two had M1, 
and two remained within normal range from the initial 
to the follow-up biopsies. Progressed cortical tubular 
atrophy occurred in only one child, and no children with 
IgAN progressed to cortical interstitial fibrosis or tubular 
atrophy due to CsA treatment (Table 3). As shown in Table 
3, one year of oral CsA treatment was not associated 
with a marked increase in mean activity index without 
an increase in chronicity. None of the renal biopsy classi-
fications worsened in either HSPN or in IgAN. 
At the latest follow-up after the end of CsA treatment, 
Table 1. Clinical Characteristics of Children with Immunoglo-
bulin A Nephritis and Henoch-Schönlein Purpura Nephritis
Total patients N=54 (%)
Diagnosis
  IgAN:HSPN 36:18 (59.3:33.3)
Sex
  male:female 32:22 (59.3:40.7)
Age (years) 10±4.2
Microscopic hematuria 54 (100)
Gross hematuria 36 (66.7)
Duration of CsA (months) 11.7±5.6
Duration of ACEI (months) 14.5±24.2
Follow-up duration (years) 3.7±3.1
Abbreviations: IgAN, Immunoglobulin A nephropathy; HSPN, Henoch- 
Schönlein purpura nephritis; CsA, cyclosporine A; ACEI, Angiotensin 
converting enzyme inhibitor
Fig. 1. Elementary renal lesions observed in patients with IgA nephropathy are shown 
repre sentatively according to the Oxford classification: a) segmental sclerosis (S1); b) 
mesangial hypercellularity (M1); and c) tubular atrophy/interstitial fibrosis >50% (T2).
Table 2. Comparison of Laboratory Data before and after the 
Treatment of Cyclosporin A
Variables Pre-treatment Post-treatment P value
Total protein (g/dL) 5.5±0.8 7.1±0.4 <0.001
Albumin (g/dL) 2.8±0.6 4.3±0.2 <0.001
Na (mMol/L) 139.5±2.7 140.2±1.7 0.040
K (mMol/L) 4.2±0.4 4.4±0.4 0.111
Cl (mMol/L) 104.4±3.3 104.8±2.0 0.691
BUN (mg/dL) 14.0±4.2 14.4±4.8 0.851
Creatinine (mg/dL) 0.6±0.2 0.7±0.2 0.005
Cholesterol (mg/dL) 205.9±77.9 166.0±44.0 <0.001
Uric acid (mg/dL) 4.8±1.3 5.3±1.6 0.004
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24 patients returned to normal urinalysis and maintained 
normal renal function (state A), 8 patients had microscopic 
hematuria without proteinuria (state B1), and 17 patients 
had proteinuria of <40 mg/m2/hr (state B2). The proportion 
of children with active renal disease with proteinuria of 
>40 mg/m2/hr (state C) was decreased from 30 (55.6%) 
to 5 (9.3%). Side effects of CsA treatment, including 
gingival hypertrophy and trichosis, were minimal, and 
no one withdrew from CsA treatment because of the 
absence of severe side effects or complications. The 
protein to creatinine ratio significantly decreased from 
3.7±1.5 to 0.6±0.4 after CsA treatment (P<0.001) (Fig. 3). 
Fig. 4 exhibits that if the basal level of proteinuria was 
set to 1, a 50% reduction in proteinuria was achieved 2.6 
months after treatment with CsA. CsA treatment was well 
tolerated in all patients, and no patients required drug 
discontinuation or had any serious adverse effects that 
warranted hospitalization. 
Fig. 2. Elementary renal lesions observed in patients with HSP nephritis are shown 
represen tatively according to the ISKDC classification: a) minimal glomerular abnor-
mality; b) pure mesangial proliferation; and c) mesangial proliferation with crescent 
formation (arrow).
Table 3. Follow-up Histological Data in 6 HSPN and 6 IgA Patients Treated with Cyclosporin A
HSPN case
1st Biopsy 2nd Biopsy
Glomeruli (n) ISKDC AI CI TI Glomeruli (n) ISKDC AI CI TI
1 32 II 2/0 0 0 39 II 1/0 0 0
2 25 IIIb 3/0 0 0 30 II 2/0 1 1
3 64 IIIa 1/0 1 0 45 IIIb 3/1 0 0
4 43 IIIb 3/1 0 0 56 II 1/0 1 2
5 29 IIIb 2/1 0 0 39 II 2/0 0 1
6 47 III 2/0 1 1 37 II 2/0 1 1
 IgAN case
 1st Biopsy 2nd Biopsy          
CIF CTA Oxford CS CIF CTA Oxford CS
1 0 0 M1E0S1T0 0 1 M1E0S1T0
2 0 0 M1E1S0T0 0 0 M1E1S0T0
3 0 0 M0E0S0T0 0 0 M0E0S0T0
4 0 0 M1E0S0T0 0 0 M1E0S0T0
5 0 0 M1E0S0T0 0 0 M1E0S0T0
6 0 0 M0E0S0T0 0 0 M0E0S0T0
Abbreviations: Bx, biopsy; ISKDC, International Study of Kidney Disease in Childhood; AI, activity index; ChI, chronicity index; TI, tubulointerstitial 
change; CIF, cortical interstitial fibrosis; CTA, cortical tubular atrophy; CS, classification system
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Discussion
As previously suggested [16, 17], IgAN and HSPN repre-
sent a spectrum of clinical and pathologic presentations 
of the same or a similar disorder, probably sharing a 
common pathogenesis. The features supporting this 
hypothesis include reports on the occurrence of these 
two diseases in the same family [18, 19], patients presenting 
with the combination of symptoms of HSP and IgAN 
[20, 21], and the indistinguishable nature of the renal 
histopathologic lesion [22]. However, according to our 
pathologic experiences, the two diseases are distingui-
shable not only in clinical presentations but also in pa-
thology. Particularly, electron microscopy reveals that 
much larger one or two electron dense deposits are 
located in paramesangium and near the capillary wall 
in IgAN, whereas characteristically small and scattered 
electron dense deposits are often within and throughout 
the mesangial regions in HSPN [23]. This pathognomonic 
feature gives us a clue to pathologically differentiate and 
diagnose the two different diseases of IgA deposits.
Although the majority of patients with IgAN have good 
prognosis, 20-30% or sometimes up to 40% of patients 
will progress to ESRD over the course of 10-20 years [1, 
2, 24]. These patients who are at high risk of progressive 
renal disease need to take a more aggressive therapeutic 
approach. Both clinical and histologic features at first 
biopsy should thoroughly be evaluated to determine 
whether the patients with IgAN are at high risk of pro-
gressive renal disease. While HSP is often a benign and 
a self-limited condition, approximately 30-90% of pe-
diatric patients develop nephritis within 4 to 6 weeks of 
the initial presentation [8]. HSP is the most common cause 
of crescentic glomerulonephritis in children, which often 
manifests hematuria and proteinuria of variable intensity 
[25]. 
The treatment of severe IgAN and HSPN is still con-
troversial, and recommendations are based on small, 
often uncontrolled series. Some studies have reported 
favorable results of treatments including intravenous 
administration of methylprednisolone followed by oral 
treatment with corticosteroids, corticosteroids in combi-
nation with azathioprine, cyclophosphamide with/with-
out anticoagulants, plasmapheresis, and mycophenolate 
mofetil [26-28]. Nevertheless, there have been only a 
few studies of CsA treatment for IgAN or HSPN, respec-
tively. Thus, the main goal of our study was to demon-
strate the clinical efficacy of CsA in glomerular diseases 
characterized by IgA deposits and particularly to determine 
whether there were any severe glomerular histologic 
changes after CsA use according to the ISKDC and the 
Oxford classification. 
Our study showed that CsA treatment has antiprote-
inuric effect in patients with glomerular injury by IgA 
deposits. In our study, there was a patient (HSPN, patient 
3) who showed histological changes from ISKDC IIIa to 
IIIb, although he achieved clinical remission in nephritic-
range proteinuria. In the remaining patients, 3 patients 
Fig. 3. Protein to creatinine ratio before and after cyclosporine 
treatment. Protein to creatinine ratio decreased from 3.7±1.5 
to 0.6±0.4 (P<0.001).
Fig. 4. Proteinuria was reduced to the half of its pretreatment 
level after 2.6 months of CsA treatment (P<0.001).
98 J Korean Soc Pediatr Nephrol  Vol. 17, No. 2, 92-100, 2013
(HSPN, patients 2, 4, and 5) showed improvements 
in histological grades (ISKDC IIIb to II in 3 patients) and 
2 patients (HSPN, patients 1 and 6) showed the same 
histological grades (ISKDC II to II in 2 patients) with clinical 
improvements. In IgAN cases, all patients showed same 
histological grades with clinical improve ments. These 
results are in accordance with those of the previous 
studies. According to a study by Shin et al. [13], nine 
patients achieved stable remission after treatment with 
CsA during a mean follow-up of 4.6 years in 14 pediatric 
IgAN patients with nephrotic-range proteinuria. In 
addi tion, the laboratory findings exhibited a decline in 
the rate of 24-hr urinary protein excretion and a signi-
ficant increase in serum albumin after CsA treatment. 
Furthermore, immunofluorescent analysis at the first 
and second biopsies showed a significant reduction of 
mesangial IgA deposits in seven (50%) of the 14 patients. 
A controlled study with a small number of patients by 
Lai et al. [29]. also demonstrated a >50% reduction in 
proteinuria in 83% of 12 cyclosporine-treated IgAN 
patients and decreased IgA levels in 80% as well as 
increased serum albumin. Ronkainen et al. also reported 
that in seven pediatric HSPN patients with nephrotic-range 
proteinuria, four patients achieved stable remission after 
treatment with CsA during a mean follow-up of 6.0 
years [9]. Consistent with these previous studies, the 
protein to creatinine ratio and urinary protein excretion in 
24-h collection significantly decreased after CsA treat-
ment in our study. However, our participants were 
different from those of previous studies in that our 
patients, who did not respond to prednisolone, did not 
receive any other immunosuppressive agents such as 
cyclophosphamide or azathioprine before CsA treatment. 
The mechanism of CsA immunosuppressive action 
in glomerular diseases is still elusive. One possible ex-
planation for the immunological basis of CsA efficacy is 
related to its ability to inhibit the secretion of cytokines 
by infiltrating T cells and macrophages [30]. In addition, 
CsA also stabilizes the podocyte actin cytoskeleton, 
resulting in reducing massive proteinuria [31]. 
Although CsA is a very effective immunosuppressive 
agent for steroid-dependent and steroid-resistant nephritic 
syndrome [32], nephrotoxicity is one adverse effect that 
limits its long-term use. Significantly increased creatinine 
level might result from CsA treatment in our study [33]. 
Notably, CsA-induced toxicity is related to the duration 
of treatment (>24 or 36 months) and dose of CsA [34, 
35]. All of our patients were carefully observed and 
monitored during the treatment period, and the trough 
level of CsA was maintained between 100-200 ng/
mL during the entire period. Due to relatively low CsA 
trough levels, there were no significant side effects that 
warranted hospitalization or discontinuation of treatment. 
The ideal duration of CsA treatment for patients with 
renal disease characterized by IgA deposits is not 
known. Our results indicated that treatment duration of 
2.6 months was necessary to achieve a 50% reduction 
of proteinuria from levels at the initial diagnosis. Thus, 
based on the result, we suggest that CsA should be 
treated for at least three months or more to achieve the 
goal of reducing massive proteinuria in patients with 
glomerular injury by IgA deposits.
The present study has some limitations: 1) this was a 
retrospective study, and the sample size was small; 2) 
the study had relatively short duration of CsA treatment 
and follow-up period; and 3) selection bias may have 
existed in that only mild patients were recruited at renal 
biopsy. 4) we were not able to analyze the date of control 
group receiving ACEi alone due to unavailability of date. 
All our patients received an ACEi, which is known to 
provide antiproteinuria and renoprotective effect against 
deterioration in renal function in various renal diseases 
[36]. Despite these limitations, the current data clearly 
show that patients with nephrotic-range proteinuria 
can effectively and safely be treated with CsA for less 
than one year. Also, the current pathologic results reveal 
that no patients treated with CsA for less than one year 
progress to renal deterioration and aggravation in the 
glomerular diseases. In other words, CsA is not inferior 
to other immunosuppressive agents in the treatment of 
patient with IgA deposits without causing renal cytoto-
xicity in one-year usage. 
In conclusion, our study indicates that CsA can be used 
to reduce massive proteinuria without any pathologic 
deterioration within one year. Additionally, our findings 
suggest that CsA treatment should be maintained for 
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at least three months or more to obtain a satisfactory 
effect on decreasing massive proteinuria in glomerular 
injury associated with IgA deposits, such as IgAN and 
HSPN.
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한글요약
목적: IgA 신병증, HSP 신병증은 사구체의 메산지움에 
IgA가 침착되는 대표적인 질환이다. 본 연구는 소아에서, 
이 두 가지 질환에 대한 Cyclosporin A 의 임상적 및 병리
학적 효과를 평가하기 위하여 시행되었다.
방법: 총 54명의 환자(IgA 신병증: Henoch-Schönlein 
purpura 신병증=36:18)를 대상으로 후향적으로 연구를 진
행하였다. CsA는 5mg/kg/day 으로 투여하였으며, 투여 전, 
후로 단백뇨의 양을 측정, 병리학적 변화를 조사하기 위
해 신생검을 시행하였다. HSP 신병증 및 IgA 신병증의 신생
검은 병리학적으로 각각 ISKDC 분류법, Oxford 분류체계
(2009)로 구분하였다. 
결과: 혈청 단백/크레아티닌 비는 치료 전후로 3.7±1.5 
에서 0.6±0.4으로 호전되었고(P<0.001), 총 54명 중 32명의 
환자(59.2%)에서 CsA 치료 1년 후 단백뇨의 관해를 보였
다. 신생검의 병리학적 소견은 호전되거나, 또는 치료 전후
로 유지되는 양상을 보였으며, CsA로 인한 합병증은 없었
다. 
결론: CsA 는 IgA의 사구체 침착을 특징으로 하는 IgA 
신병증, HSP 신병증 환자에서 단백뇨 감소효과 및 말기신
부전으로의 진행을 예방하는 데에 효과적인 것으로 사료
된다.
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